Jundishapur Journal of Natural Pharmaceutical Products

Published by: Kowsar

Circulating miR-122 and miR-192 as Specific and Sensitive Biomarkers for Drug-Induced Liver Injury with Acetaminophen in Rats

Pouria Jarsiah 1 , Mohammad Karami 1 , Anahita Nosrati 2 , Ahad Alizadeh 3 and Mohammad Bagher Hashemi-Soteh 4 , *
Authors Information
1 Department of Toxicology and Pharmacology, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran
2 Laboratory of Pathobiology, Imam Khomeini Hospital, Sari, Iran
3 Department of Epidemiology and Reproductive Health, Reproductive Epidemiology Research Center, Royan Institute for Reproductive Biomedicine, ACECR, Tehran, Iran
4 Immunogenetic Research Center, Molecular and Cell biology Research Center, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran
Article information
  • Jundishapur Journal of Natural Pharmaceutical Products: May 31, 2019, 14 (2); e65678
  • Published Online: December 16, 2018
  • Article Type: Research Article
  • Received: December 28, 2017
  • Revised: April 15, 2018
  • Accepted: May 14, 2018
  • DOI: 10.5812/jjnpp.65678

To Cite: Jarsiah P, Karami M, Nosrati A, Alizadeh A, Hashemi-Soteh M B. Circulating miR-122 and miR-192 as Specific and Sensitive Biomarkers for Drug-Induced Liver Injury with Acetaminophen in Rats, Jundishapur J Nat Pharm Prod. 2019 ; 14(2):e65678. doi: 10.5812/jjnpp.65678.

Abstract
Copyright © 2018, Jundishapur Journal of Natural Pharmaceutical Products. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Tamai S, Iguchi T, Niino N, Mikamoto K, Sakurai K, Sayama A, et al. A monkey model of acetaminophen-induced hepatotoxicity; phenotypic similarity to human. J Toxicol Sci. 2017;42(1):73-84. doi: 10.2131/jts.42.73. [PubMed: 28070111].
  • 2. Fontana RJ. Acute liver failure due to drugs. Semin Liver Dis. 2008;28(2):175-87. doi: 10.1055/s-2008-1073117. [PubMed: 18452117].
  • 3. Davis DC, Potter WZ, Jollow DJ, Mitchell JR. Species differences in hepatic glutathione depletion, covalent binding and hepatic necrosis after acetaminophen. Life Sci. 1974;14(11):2099-109. doi: 10.1016/0024-3205(74)90092-7. [PubMed: 4847802].
  • 4. Ozer JS, Chetty R, Kenna G, Palandra J, Zhang Y, Lanevschi A, et al. Enhancing the utility of alanine aminotransferase as a reference standard biomarker for drug-induced liver injury. Regul Toxicol Pharmacol. 2010;56(3):237-46. doi: 10.1016/j.yrtph.2009.11.001. [PubMed: 19903504].
  • 5. Thulin P, Hornby RJ, Auli M, Nordahl G, Antoine DJ, Starkey Lewis P, et al. A longitudinal assessment of miR-122 and GLDH as biomarkers of drug-induced liver injury in the rat. Biomarkers. 2017;22(5):461-9. doi: 10.1080/1354750X.2016.1269131. [PubMed: 27978773].
  • 6. Starkey Lewis PJ, Dear J, Platt V, Simpson KJ, Craig DG, Antoine DJ, et al. Circulating microRNAs as potential markers of human drug-induced liver injury. Hepatology. 2011;54(5):1767-76. doi: 10.1002/hep.24538. [PubMed: 22045675].
  • 7. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008;105(30):10513-8. doi: 10.1073/pnas.0804549105. [PubMed: 18663219]. [PubMed Central: PMC2492472].
  • 8. Hanke M, Hoefig K, Merz H, Feller AC, Kausch I, Jocham D, et al. A robust methodology to study urine microRNA as tumor marker: MicroRNA-126 and microRNA-182 are related to urinary bladder cancer. Urol Oncol. 2010;28(6):655-61. doi: 10.1016/j.urolonc.2009.01.027. [PubMed: 19375957].
  • 9. Coulouarn C, Factor VM, Andersen JB, Durkin ME, Thorgeirsson SS. Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Oncogene. 2009;28(40):3526-36. doi: 10.1038/onc.2009.211. [PubMed: 19617899]. [PubMed Central: PMC3492882].
  • 10. Roderburg C, Luedde M, Vargas Cardenas D, Vucur M, Scholten D, Frey N, et al. Circulating microRNA-150 serum levels predict survival in patients with critical illness and sepsis. PLoS One. 2013;8(1). e54612. doi: 10.1371/journal.pone.0054612. [PubMed: 23372743]. [PubMed Central: PMC3555785].
  • 11. Ben-Shachar R, Chen Y, Luo S, Hartman C, Reed M, Nijhout HF. The biochemistry of acetaminophen hepatotoxicity and rescue: A mathematical model. Theor Biol Med Model. 2012;9:55. doi: 10.1186/1742-4682-9-55. [PubMed: 23249634]. [PubMed Central: PMC3576299].
  • 12. Kong YW, Ferland-McCollough D, Jackson TJ, Bushell M. microRNAs in cancer management. Lancet Oncol. 2012;13(6):e249-58. doi: 10.1016/S1470-2045(12)70073-6. [PubMed: 22652233].
  • 13. Yamaura Y, Nakajima M, Takagi S, Fukami T, Tsuneyama K, Yokoi T. Plasma microRNA profiles in rat models of hepatocellular injury, cholestasis, and steatosis. PLoS One. 2012;7(2). e30250. doi: 10.1371/journal.pone.0030250. [PubMed: 22363424]. [PubMed Central: PMC3281829].
  • 14. Roderburg C, Benz F, Vargas Cardenas D, Koch A, Janssen J, Vucur M, et al. Elevated miR-122 serum levels are an independent marker of liver injury in inflammatory diseases. Liver Int. 2015;35(4):1172-84. doi: 10.1111/liv.12627. [PubMed: 25039534].
  • 15. Reid G, Kirschner MB, van Zandwijk N. Circulating microRNAs: Association with disease and potential use as biomarkers. Crit Rev Oncol Hematol. 2011;80(2):193-208. doi: 10.1016/j.critrevonc.2010.11.004. [PubMed: 21145252].
  • 16. Hornby RJ, Starkey Lewis P, Dear J, Goldring C, Park BK. MicroRNAs as potential circulating biomarkers of drug-induced liver injury: Key current and future issues for translation to humans. Expert Rev Clin Pharmacol. 2014;7(3):349-62. doi: 10.1586/17512433.2014.904201. [PubMed: 24694030].
  • 17. Jarsiah P, Nosrati A, Alizadeh A, Hashemi-Soteh SMB. Hepatotoxicity and ALT/AST enzymes activities change in therapeutic and toxic doses consumption of acetaminophen in rats. Int Biolog Biomed J. 2017;3(3):119-24.
  • 18. Cheung L, Gustavsson C, Norstedt G, Tollet-Egnell P. Sex-different and growth hormone-regulated expression of microRNA in rat liver. BMC Mol Biol. 2009;10:13. doi: 10.1186/1471-2199-10-13. [PubMed: 19236699]. [PubMed Central: PMC2654566].
  • 19. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25(4):402-8. doi: 10.1006/meth.2001.1262. [PubMed: 11846609].
  • 20. Rangnekar AS, Fontana RJ. An update on drug induced liver injury. Minerva Gastroenterol Dietol. 2011;57(2):213-29. [PubMed: 21587150].
  • 21. Antoine DJ, Mercer AE, Williams DP, Park BK. Mechanism-based bioanalysis and biomarkers for hepatic chemical stress. Xenobiotica. 2009;39(8):565-77. doi: 10.1080/00498250903046993. [PubMed: 19621999].
  • 22. Ozer J, Ratner M, Shaw M, Bailey W, Schomaker S. The current state of serum biomarkers of hepatotoxicity. Toxicology. 2008;245(3):194-205. doi: 10.1016/j.tox.2007.11.021. [PubMed: 18291570].
  • 23. Starckx S, Batheja A, Verheyen GR, Jonghe SD, Steemans K, Dijck BV, et al. Evaluation of miR-122 and other biomarkers in distinct acute liver injury in rats. Toxicol Pathol. 2013;41(5):795-804. doi: 10.1177/0192623312464436. [PubMed: 23143187].
  • 24. Antoine DJ, Dear JW, Lewis PS, Platt V, Coyle J, Masson M, et al. Mechanistic biomarkers provide early and sensitive detection of acetaminophen-induced acute liver injury at first presentation to hospital. Hepatology. 2013;58(2):777-87. doi: 10.1002/hep.26294. [PubMed: 23390034]. [PubMed Central: PMC3842113].
  • 25. Wu C, Zhang J, Cao X, Yang Q, Xia D. Effect of Mir-122 on human cholangiocarcinoma proliferation, invasion, and apoptosis through P53 expression. Med Sci Monit. 2016;22:2685-90. doi: 10.12659/MSM.896404. [PubMed: 27472451]. [PubMed Central: PMC4976756].
  • 26. Wang K, Zhang S, Marzolf B, Troisch P, Brightman A, Hu Z, et al. Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proc Natl Acad Sci U S A. 2009;106(11):4402-7. doi: 10.1073/pnas.0813371106. [PubMed: 19246379]. [PubMed Central: PMC2657429].
  • 27. Salamin O, Jaggi L, Baume N, Robinson N, Saugy M, Leuenberger N. Circulating microRNA-122 as potential biomarker for detection of testosterone abuse. PLoS One. 2016;11(5). e0155248. doi: 10.1371/journal.pone.0155248. [PubMed: 27171140]. [PubMed Central: PMC4865044].
  • 28. Sharapova T, Devanarayan V, LeRoy B, Liguori MJ, Blomme E, Buck W, et al. Evaluation of miR-122 as a serum biomarker for hepatotoxicity in investigative rat toxicology studies. Vet Pathol. 2016;53(1):211-21. doi: 10.1177/0300985815591076. [PubMed: 26123229].
  • 29. Chang J, Guo JT, Jiang D, Guo H, Taylor JM, Block TM. Liver-specific microRNA miR-122 enhances the replication of hepatitis C virus in nonhepatic cells. J Virol. 2008;82(16):8215-23. doi: 10.1128/JVI.02575-07. [PubMed: 18550664]. [PubMed Central: PMC2519557].
  • 30. Zhang X, Zhang Z, Dai F, Shi B, Chen L, Zhang X, et al. Comparison of circulating, hepatocyte specific messenger RNA and microRNA as biomarkers for chronic hepatitis B and C. PLoS One. 2014;9(3). e92112. doi: 10.1371/journal.pone.0092112. [PubMed: 24643113]. [PubMed Central: PMC3958472].

Featured Image:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments